Alaunos Therapeutics to Participate in Upcoming Investor Conferences in September

Rhea-AI Summary

HOUSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, announced participation in several investor conferences. Key events include:

• Wells Fargo Healthcare Conference on September 8, 2022, in Boston, MA (1x1 Meetings)
• Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, in New York, NY (1x1 Meetings)
• Cantor Oncology Conference on September 28, 2022, in New York, NY (Panel Presentation and 1x1 Meetings)

The company specializes in T-cell receptor therapies targeting tumor-specific mutations.

HOUSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger, Ph.D., Vice President, Research & Development will be participating in the following upcoming investor conferences.

2022 Wells Fargo Healthcare Conference
Date: Thursday, September 8, 2022
Format: 1x1 Meetings only
Location: Boston, MA

Morgan Stanley 20^th Annual Global Healthcare Conference
Date: Monday, September 12, 2022
Format: 1x1 Meetings only
Location: New York, NY

Cantor Oncology, Hematology & HemeOnc Conference
Date: Wednesday, September 28, 2022
Format: Panel Presentation and 1x1 Meetings
Panel: Cell Therapy in Solid Tumors
Location: New York, NY

About Alaunos Therapeutics
Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its proprietary, non-viral Sleeping Beauty gene transfer technology and its TCR library targeting shared tumor-specific hotspot mutations in key oncogenic genes including KRAS, TP53 and EGFR. The Company has a clinical and strategic collaboration with the National Cancer Institute. For more information, please visit www.alaunos.com.

Investor Relations Contact:
Alex Lobo
Stern Investor Relations
alex.lobo@sternir.com

FAQ

What conferences is Alaunos Therapeutics attending in September 2022?

Alaunos Therapeutics is attending the Wells Fargo Healthcare Conference on September 8, 2022, the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, and the Cantor Oncology Conference on September 28, 2022.

What is the focus of Alaunos Therapeutics?

Alaunos Therapeutics focuses on developing oncology-based cell therapies using T-cell receptor technology targeting specific tumor mutations.

What is the ticker symbol for Alaunos Therapeutics?

The ticker symbol for Alaunos Therapeutics is TCRT.

Who are the key executives participating in the conferences?

Kevin S. Boyle Sr., CEO, and Drew Deniger, Ph.D., VP of Research & Development, are the key executives participating in the upcoming conferences.

What technology does Alaunos Therapeutics utilize for its therapies?

Alaunos Therapeutics utilizes its proprietary non-viral Sleeping Beauty gene transfer technology to develop its T-cell receptor therapies.